RESUMEN
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective for glycemic control, with many also demonstrating cardiovascular (CV) benefit, in people with type 2 diabetes (T2D). This study aimed to find a consensus on the barriers and strategies for the optimal use of GLP-1 RAs in people with T2D and high CV risk or established cardiovascular disease (CVD) in Spain. METHODS: A two-round Delphi survey (53 questions) was conducted among members of four national scientific societies in Spain, including physicians experienced in the management of people with T2D. The degree of consensus was evaluated with a 7-point Likert scale, establishing consensus when ≥ 70% of the panelists agreed (6-7) or disagreed (1-2). RESULTS: A total of 97 physicians participated in the first round (endocrinology: 34%, family and community medicine: 21%, internal medicine: 23%, and cardiology: 23%), and 96 in the second round. The main barriers identified were: therapeutic inertia and late use of GLP-1 RAs; lack of a comprehensive approach to CV risk; lack of knowledge on the usefulness of GLP-1 RAs in CVD prevention and treatment; and economic/administrative barriers. Strategies with a highest consensus included: the need to establish simple protocols that integrate awareness of CV risk monitoring; training professionals and patients; and the use of new technologies. CONCLUSION: Physicians identified clinical, healthcare, and economic/administrative barriers that limit the use of GLP-1 RAs in people with T2D and high CV risk or established CVD in Spain, highlighting the importance of integrating these therapies according to clinical practice guidelines.
RESUMEN
In recent years, sensory polymers have evolved significantly, emerging as versatile and cost-effective materials valued for their flexibility and lightweight nature. These polymers have transformed into sophisticated, active systems capable of precise detection and interaction, driving innovation across various domains, including smart materials, biomedical diagnostics, environmental monitoring, and industrial safety. Their unique responsiveness to specific stimuli has sparked considerable interest and exploration in numerous applications. However, along with these advancements, notable challenges need to be addressed. Issues such as wearable technology integration, biocompatibility, selectivity and sensitivity enhancement, stability and reliability improvement, signal processing optimization, IoT integration, and data analysis pose significant hurdles. When considered collectively, these challenges present formidable barriers to the commercial viability of sensory polymer-based technologies. Addressing these challenges requires a multifaceted approach encompassing technological innovation, regulatory compliance, market analysis, and commercialization strategies. Successfully navigating these complexities is essential for unlocking the full potential of sensory polymers and ensuring their widespread adoption and impact across industries, while also providing guidance to the scientific community to focus their research on the challenges of polymeric sensors and to understand the future prospects where research efforts need to be directed.
RESUMEN
INTRODUCTION/OBJECTIVES: The use of non-occupational post-exposure prophylaxis (nPEP) emerges as a strategic intervention to reduce HIV infection risk following sexual encounters in our setting. Notwithstanding, there is a scarcity of contemporary data regarding adherence to this treatment, its effectiveness and tolerance. Our study aims to delve into these factors among individuals who have resorted to nPEP after high-risk sexual encounters. METHODS: We conducted a retrospective observational study of cases administered nPEP for HIV from 1 January 2018 to 31 December 2021 at a tertiary hospital in Madrid. The study included all adults over 18 years who sought care at the emergency department of the Fundación Jiménez Díaz Hospital following a risky sexual encounter and were subsequently recommended HIV nPEP treatment. RESULTS: 878 individuals received nPEP for HIV and underwent initial serological tests. Of these, 621 had comprehensive follow-ups. The prescribed regimen for all was raltegravir (RAL) 1200 mg combined with tenofovir/emtricitabine (TDF/FTC) 245/200 mg daily for 28 days. The study revealed a 1.1% rate (n=10) of previously undetected infection and a 0.16% (n=1) failure rate of nPEP. Regarding regimen tolerability, 5.6% (n=35) experienced symptoms linked to the treatment, yet none necessitated discontinuation of the regimen. On the contrary, six per cent (n=53) reported symptoms consistent with an STI during one of the medical visits; specifically, 4.4% had urethritis, and 1.6% had proctitis. CONCLUSION: nPEP with RAL/TDF/FTC demonstrates high efficacy and safety, contingent on proper adherence. There is an observed increase in STI prevalence in this cohort, with nearly half of the participants not engaging in appropriate follow-up after initiating nPEP.
Asunto(s)
Fármacos Anti-VIH , Infecciones por VIH , Profilaxis Posexposición , Humanos , Infecciones por VIH/prevención & control , Infecciones por VIH/epidemiología , Masculino , Estudios Retrospectivos , Adulto , Femenino , Fármacos Anti-VIH/uso terapéutico , Fármacos Anti-VIH/administración & dosificación , Persona de Mediana Edad , España/epidemiología , Cumplimiento de la Medicación/estadística & datos numéricos , Adulto JovenRESUMEN
Introduction: Atherosclerotic cardiovascular disease (ASCVD) is one of the main causes of morbidity and mortality in developed countries and entails high resources use and costs for health systems. The risk of suffering future cardiovascular (CV) events and the consequent resources use is higher in those patients who have already had a previous cardiovascular event. The objective of the study was to determine the average annual cost of patients with a new or recurrent atherosclerotic CV event during the 2 years after the event. Methodology: Retrospective observational study of electronic medical records of patients from the BIG-PAC® database (7 integrated health areas of 7 Autonomous Communities; n = 1.8 million). Patients with a new or recurrent episode of ASCVD (angina, acute myocardial infarction, transient ischemic attack, stroke, or peripheral arterial disease) between 1-Jan-2017 and 31-Dec-2018 were included. The resources use within two years of the diagnosis was estimated in order to estimate the average cost of patient follow-up. Results: A total of 26,976 patients with an ASCVD episode were identified during the recruitment period; Out of them, 6,798 had a recurrent event during the follow-up period and 2,414 died. The average costs per patient were 11,171 during the first year and 9,944 during the second year. Discussion: Patients with ASCVD represent a significant economic burden for the health system and for society. Despite the perception that drug costs in the follow-up of chronic patients imply a high percentage of the costs, these accounted for only one tenth of the total amount. Implementing preventive programs and increasing the control of cardiovascular risk factors may have a significant social and health impact by helping to reduce mortality and costs for the Spanish National Health System. The costs derived from pharmacological treatments were obtained from the NHS pricing nomenclator database (https://www.sanidad.gob.es/profesionales/nomenclator.do).
RESUMEN
AIM: To reach a multidisciplinary consensus on managing patients with type 2 diabetes among specialists in family medicine, cardiology, endocrinology, internal medicine, and nephrology. METHODS: A two-round Delphi study was conducted using a questionnaire with 68 positive/negative statements distributed in four thematic blocks on diabetes management: early diagnosis and prediabetes, referral criteria, treatment and comorbidities, and clinical management. The expert panel was composed of 105 physicians from different specialties (family medicine, cardiology, endocrinology, internal medicine, and nephrology) with experience in managing patients with diabetes and who were members of a diabetes-related society. RESULTS: Response rates for the first and second rounds were 86.7 and 75.2%, respectively. After both rounds, a consensus was reached on 52 (76.5%) items. The recommendations with the highest degree of consensus (median = 10, IQR = 0.00) were related to anti-smoking education, cardiovascular risk factor target control, and diabetic kidney disease. There were significant differences between family physicians and other specialties for some items. CONCLUSIONS: This study provides a set of recommendations for diabetes management agreed upon by specialists from different healthcare settings.
Asunto(s)
Diabetes Mellitus Tipo 2 , Humanos , Diabetes Mellitus Tipo 2/terapia , Consenso , Técnica Delphi , Comorbilidad , Encuestas y CuestionariosRESUMEN
Introducción y objetivos: La estrategia de prevención cardiovascular en las comunidades autónomas (CCAA) puede ser variable, al estar transferidas las competencias en sanidad. El objetivo del estudio fue conocer el control de la dislipemia y la terapia hipolipemiante utilizada en pacientes de alto/muy alto riesgo cardiovascular (RCV) por CCAA. Métodos: Estudio descriptivo, transversal, multicéntrico no aleatorizado basado en una metodología de consenso. Se recogió información de práctica clínica en 145 áreas sanitarias de 17CCAA españolas mediante reuniones presenciales y cuestionarios realizados a los 435 médicos participantes. Se recopilaron datos agregados no identificables de 10 pacientes dislipémicos consecutivos que cada participante hubiera visitado recientemente. Resultados: De los 4.010 pacientes compilados, 649 (16%) eran de alto y 2.458 (61%) de muy alto RCV. La distribución de los 3.107 pacientes de alto/muy alto RCV fue equilibrada entre regiones, pero hubo diferencias interterritoriales (p<0,0001) en la consecución del objetivo de cLDL<70 e <55mg/dl, respectivamente. Las estatinas de alta intensidad en monoterapia o combinadas con ezetimiba y/o inhibidores PCSK9 se utilizaron en el 44, el 21 y el 4% de los pacientes de alto RCV, mientras que en los de muy alto RCV era del 38, del 45 y del 6%, respectivamente. El uso de estas terapias hipolipemiantes a nivel nacional fue significativamente diferente entre regiones (p=0,0079). Conclusiones: A pesar de que la distribución de los pacientes de alto/muy alto RCV fue similar entre CCAA, se identificaron diferencias interterritoriales en el grado de consecución del objetivo terapéutico en cLDL y de utilización de la terapia hipolipemiante. (AU)
Introduction and objective: The cardiovascular prevention strategy by autonomous communities can be variable since the competences in health are transferred. The objective of the study was to determine the degree of dyslipidaemia control and the lipid-lowering pharmacological therapy used in patients at high/very high cardiovascular risk (CVR) by autonomous communities. Methods: Observational, cross-sectional, descriptive study based on a consensus methodology. Information on the clinical practice of 145 health areas belonging to 17 Spanish autonomous communities was collected through face-to-face meetings and questionnaires administered to the 435 participating physicians. Furthermore, aggregate non-identifiable data were compiled from 10 consecutive dyslipidaemic patients that each participant had recently visited. Results: Of the 4010 patients collected, 649 (16%) had high and 2458 (61%) very high CVR. The distribution of the 3107 high/very high CVR patients was balanced across regions, but there were inter-regional differences (P<.0001) in the achievement of target LDL-C <70 and <55mg/dL, respectively. High-intensity statins in monotherapy or in combination with ezetimibe and/or PCSK9 inhibitors were used in 44, 21 and 4% of high CVR patients, while in those at very high CVR it rose to 38, 45 and 6%, respectively. The use of these lipid-lowering therapies at national level was significantly different between regions (P=.0079). Conclusions: Even though the distribution of patients at high/very high CVR was similar between autonomous communities, inter-territorial differences were identified in the degree of achievement of LDL cholesterol therapeutic goal and use of lipid-lowering therapy. (AU)
Asunto(s)
Humanos , Hiperlipidemias/prevención & control , Enfermedades Cardiovasculares/terapia , Hipolipemiantes/uso terapéutico , Estudios Transversales , Epidemiología Descriptiva , España , Enfermedades Cardiovasculares/prevención & controlRESUMEN
Las enfermedades cardiovasculares (ECV) siguen siendo la principal causa de muerte en nuestro país. El control adecuado de las alteraciones del metabolismo lipídico es un reto clave en prevención cardiovascular que está lejos de alcanzarse en la práctica clínica real. Existe una gran heterogeneidad en los informes del metabolismo lipídico de los laboratorios clínicos españoles, lo que puede contribuir al mal control del mismo. Por ello, un grupo de trabajo de las principales sociedades científicas implicadas en la atención de los pacientes de riesgo vascular hemos elaborado este documento con una propuesta básica de consenso sobre la determinación del perfil lipídico básico en prevención cardiovascular, recomendaciones para su realización y unificación de criterios para incorporar los objetivos de control lipídico adecuados al riesgo vascular de los pacientes en los informes de laboratorio (AU)
Cardiovascular diseases (CVD) continue to be the main cause of death in our country. Adequate control of lipid metabolism disorders is a key challenge in cardiovascular prevention that is far from being achieved in real clinical practice. There is a great heterogeneity in the reports of lipid metabolism from Spanish clinical laboratories, which may contribute to its poor control. For this reason, a working group of the main scientific societies involved in the care of patients at vascular risk, has prepared this document with a consensus proposal on the determination of the basic lipid profile in cardiovascular prevention, recommendations for its realization and unification of criteria to incorporate the lipid control goals appropriate to the vascular risk of the patients in the laboratory reports (AU)
Asunto(s)
Humanos , Enfermedades Cardiovasculares/sangre , Técnicas de Laboratorio Clínico , Laboratorios , Lípidos/sangre , Enfermedades Cardiovasculares/diagnóstico , Enfermedades Cardiovasculares/prevención & controlRESUMEN
Las enfermedades cardiovasculares (ECV) siguen siendo la principal causa de muerte en nuestro país. El control adecuado de las alteraciones del metabolismo lipídico es un reto clave en prevención cardiovascular que está lejos de alcanzarse en la práctica clínica real. Existe una gran heterogeneidad en los informes del metabolismo lipídico de los laboratorios clínicos españoles, lo que puede contribuir al mal control del mismo. Por ello, un grupo de trabajo de las principales sociedades científicas implicadas en la atención de los pacientes de riesgo vascular hemos elaborado este documento con una propuesta básica de consenso sobre la determinación del perfil lipídico básico en prevención cardiovascular, recomendaciones para su realización y unificación de criterios para incorporar los objetivos de control lipídico adecuados al riesgo vascular de los pacientes en los informes de laboratorio. (AU)
Cardiovascular diseases (CVD) continue to be the main cause of death in our country. Adequate control of lipid metabolism disorders is a key challenge in cardiovascular prevention that is far from being achieved in real clinical practice. There is a great heterogeneity in the reports of lipid metabolism from Spanish clinical laboratories, which may contribute to its poor control. For this reason, a working group of the main scientific societies involved in the care of patients at vascular risk, has prepared this document with a consensus proposal on the determination of the basic lipid profile in cardiovascular prevention, recommendations for its realization and unification of criteria to incorporate the lipid control goals appropriate to the vascular risk of the patients in the laboratory reports. (AU)
Asunto(s)
Humanos , Enfermedades Cardiovasculares/prevención & control , Lípidos , Consenso , España , Laboratorios , Bioquímica , Colesterol , LipoproteínasRESUMEN
Las enfermedades cardiovasculares (ECV) siguen siendo la principal causa de muerte en nuestro país. El control adecuado de las alteraciones del metabolismo lipídico es un reto clave en prevención cardiovascular que está lejos de alcanzarse en la práctica clínica real. Existe una gran heterogeneidad en los informes del metabolismo lipídico de los laboratorios clínicos españoles, lo que puede contribuir al mal control del mismo. Por ello, un grupo de trabajo de las principales sociedades científicas implicadas en la atención de los pacientes de riesgo vascular hemos elaborado este documento con una propuesta básica de consenso sobre la determinación del perfil lipídico básico en prevención cardiovascular, recomendaciones para su realización y unificación de criterios para incorporar los objetivos de control lipídico adecuados al riesgo vascular de los pacientes en los informes de laboratorio.(AU)
Cardiovascular diseases (CVD) continue to be the main cause of death in our country. Adequate control of lipid metabolism disorders is a key challenge in cardiovascular prevention that is far from being achieved in real clinical practice. There is a great heterogeneity in the reports of lipid metabolism from Spanish clinical laboratories, which may contribute to its poor control. For this reason, a working group of the main scientific societies involved in the care of patients at vascular risk, has prepared this document with a consensus proposal on the determination of the basic lipid profile in cardiovascular prevention, recommendations for its realization and unification of criteria to incorporate the lipid control goals appropriate to the vascular risk of the patients in the laboratory reports.(AU)
Asunto(s)
Humanos , Laboratorios , Lípidos , Colesterol , Triglicéridos , Lipoproteína(a) , España , Consenso , Enfermedades CardiovascularesRESUMEN
Las enfermedades cardiovasculares (ECV) siguen siendo la principal causa de muerte en nuestro país. El control adecuado de las alteraciones del metabolismo lipídico es un reto clave en prevención cardiovascular que está lejos de alcanzarse en la práctica clínica real. Existe una gran heterogeneidad en los informes del metabolismo lipídico de los laboratorios clínicos españoles, lo que puede contribuir al mal control del mismo. Por ello, un grupo de trabajo de las principales sociedades científicas implicadas en la atención de los pacientes de riesgo vascular, hemos elaborado este documento con una propuesta básica de consenso sobre la determinación del perfil lipídico básico en prevención cardiovascular, recomendaciones para su realización y unificación de criterios para incorporar los objetivos de control lipídico adecuados al riesgo vascular de los pacientes en los informes de laboratorio.(AU)
Cardiovascular diseases (CVD) continue to be the main cause of death in Spain. Adequate control of lipid metabolism disorders is a key challenge in cardiovascular prevention that is far from achieved in real clinical practice. There is a major heterogeneity in the reports of lipid metabolism from Spanish clinical laboratories, which may contribute to its poor monitoring. For this reason, a working group of the main scientific societies involved in the care of patients at vascular risk, has drawn up this document with a consensus proposal on the determination of the basic lipid profile in cardiovascular prevention, recommendations for its implementation and combining the criteria to incorporate the lipid monitoring goals suitable for the vascular risk of the patients in the laboratory reports.(AU)
Asunto(s)
Humanos , Laboratorios de Hospital , Servicios de Laboratorio Clínico , Laboratorios , Lípidos , Colesterol , Enfermedades Cardiovasculares , Apolipoproteínas B , España , Consenso , 35170RESUMEN
A educação em saúde e o acesso à informação são ferramentas estratégicas para a promoção do autocuidado de pessoas vivendo com HIV. Apesar dos grandes avanços científicos, sobretudo quanto ao uso da TARV, ainda existem desafios a serem enfrentados como o preconceito, o estigma e a desinformação da população. Nesse sentido, tal estratégia contribui com a adesão ao tratamento, por meio do esclarecimento de dúvidas a cerca da infecção pelo HIV. Trata-se de um relato de experiência referente às ações de educação em saúde realizadas em serviços especializados de saúde para o tratamento de pessoas vivendo com HIV. Os participantes do projeto foram capacitados e realizaram ações de educação em saúde, para abordar temas relacionados ao HIV/Aids e para o esclarecimento de dúvidas a respeito da terapia antirretroviral. Conclui-se que a integração dos serviços de saúde com as instituições de ensino se constitui com uma importante estratégia para o desenvolvimento de reflexões críticas acerca da temática, bem como para auxiliar nos cuidados direcionados às pessoas que vivem com HIV. PALAVRAS-CHAVE: Educação em Saúde; HIV; Terapia Antirretroviral; Adesão ao Tratamento.
Health education and access to information are strategic tools for promoting self-care for people living with HIV. Despite the great scientific advances, especially regarding the use of ART, there are still challenges to be faced, such as prejudice, stigma and misinformation of the population. In this sense, such a strategy contributes to adherence to treatment, by clarifying doubts about HIV infection. This is an experience report regarding health education actions carried out in specialized health services for the treatment of people living with HIV. Project participants were trained and carried out health education actions to address issues related to HIV/AIDS and to clarify doubts about antiretroviral therapy. It is concluded that the integration of health services with educational institutions constitutes an important strategy for the development of critical reflections on the subject, as well as to assist in the care directed to people living with HIV.
La educación sanitaria y el acceso a la información son herramientas estratégicas para promover el autocuidado de las personas que viven con VIH. Apesar de los grandes avances científicos, especialmente en lo que respecta al uso de las TAR, todavía quedan desafíos por afrontar, como los prejuicios, el estigma y la desinformación de la población. En este sentido, dicha estrategia contribuye a la adherencia al tratamiento, al aclarar dudas sobre la infección por VIH. Este es un relato de experiencia sobre acciones de educación en salud realizadas en servicios de salud especializados para el tratamiento de personas que viven con VIH. Los participantes del proyecto fueron capacitados y realizaron acciones de educación en salud para abordar temas relacionados con el VIH/SIDA y aclarar dudas sobre la terapia antirretroviral. Se concluye que la integración de los servicios de salud con las instituciones educativas constituye una estrategia importante para el desarrollo de reflexiones críticas sobre el tema, así como para coadyuvar en la atención dirigida a las personas que viven con VIH.
RESUMEN
El medioambiente es un gran determinante de la salud cardiovascular. La cardiología ambiental estudia la contribución de las exposiciones ambientales con el objetivo de minimizar las influencias nocivas de la contaminación y promover la salud cardiovascular mediante estrategias preventivas o terapéuticas específicas. La presente revisión se centra en el material particulado y los metales, contaminantes con la evidencia científica más sólida, e incluye las posibles intervenciones. La legislación, la mitigación y el control de los contaminantes en el aire, el agua y los alimentos y las políticas ambientales de espacios cardiosaludables son medidas clave para la salud cardiovascular. Entre las estrategias individuales, cabe reseñar la quelación de metales divalentes como el plomo y el cadmio, que solamente pueden eliminarse del cuerpo vía quelación. El ensayo clínico TACT (NCT00044213) demostró el beneficio cardiovascular en pacientes con un infarto de miocardio previo, especialmente en los diabéticos. Actualmente, el ensayo TACT2 (NCT02733185) está reproduciendo los resultados del TACT en personas con diabetes. Datos de Estados Unidos y Argentina también han mostrado la posible utilidad de la quelación en la enfermedad arterial periférica grave. Más investigación y acción en cardiología ambiental podría contribuir sustancialmente a mejorar la prevención y el tratamiento de las enfermedades cardiovasculares.(AU)
The environment is a strong determinant of cardiovascular health. Environmental cardiology studies the contribution of environmental exposures with the aim of minimizing the harmful influences of pollution and promoting cardiovascular health through specific preventive or therapeutic strategies. The present review focuses on particulate matter and metals, which are the pollutants with the strongest level of scientific evidence, and includes possible interventions. Legislation, mitigation and control of pollutants in air, water and food, as well as environmental policies for heart-healthy spaces, are key measures for cardiovascular health. Individual strategies include the chelation of divalent metals such as lead and cadmium, metals that can only be removed from the body via chelation. The TACT (Trial to Assess Chelation Therapy, NCT00044213) clinical trial demonstrated cardiovascular benefit in patients with a previous myocardial infarction, especially in those with diabetes. Currently, the TACT2 trial (NCT02733185) is replicating the TACT results in people with diabetes. Data from the United States and Argentina have also shown the potential usefulness of chelation in severe peripheral arterial disease. More research and action in environmental cardiology could substantially help to improve the prevention and treatment of cardiovascular disease.(AU)
Asunto(s)
Humanos , Ambiente , Metales , Contaminación del Aire , Material Particulado , Enfermedades Cardiovasculares , Contaminantes del Agua , Contaminantes Atmosféricos , Cardiología , CardiopatíasRESUMEN
Introducción y objetivos: El tratamiento de las dislipemias presenta gran variabilidad en la práctica clínica e importantes limitaciones que dificultan la consecución de los objetivos terapéuticos. Por ello, se ha diseñado un proyecto para evaluar el control de la dislipemia en España, identificar los puntos de mejora y tratar de optimizarlo. El objetivo de este artículo es describir la metodología del observatorio del tratamiento del paciente dislipémico en España. Métodos: Observatorio de recogida de información basada en la práctica clínica habitual y experiencia de los profesionales de la salud que atienden a pacientes dislipémicos en España. El observatorio recoge información por área sanitaria, a través de: (i) reunión presencial con tres especialidades médicas diferentes y (ii) información cuantitativa de manejo de pacientes con hipercolesterolemia (cuestionario ad hoc). La información incluye perfiles de paciente atendidos, carga asistencial, guías y protocolos utilizados, grado de control alcanzado, limitaciones y oportunidades de mejora en práctica clínica. Resultados: Se busca incluir 145 áreas sanitarias, contando con la participación de hasta 435 profesionales médicos de las 17 Comunidades Autónomas de España. La información recogida de los participantes permitirá disponer de datos agregados de más de 4.000 pacientes. Conclusiones: Este observatorio pretende conocer cómo se está tratando la hipercolesterolemia en la práctica clínica en España. Aunque los resultados preliminares muestran una importante área de mejora en el tratamiento de las dislipemias, se identifican también mecanismos para impulsar un cambio hacia la optimización de resultados en salud.(AU)
Introduction and objectives: The treatment of dyslipidemia exhibits wide variability in clinical practice and important limitations that make lipid-lowering goals more difficult to attain. Getting to know the management of these patients in clinical practice is key to understand the existing barriers and to define actions that contribute to achieving the therapeutic goals from the most recent Clinical Practice Guidelines. Methods: Observatory where the information gathered is based on routine clinical practice and the experience from the healthcare professionals involved in the treatment of dyslipidemia in Spain. The information is collected by health area through: (i) face-to-face meeting with three different medical specialties and (ii) quantitative information related to hypercholesterolemia patients management (ad-hoc questionnaire). Information includes patients profiles, assistance burden, guidelines and protocols used, goal attainment, limitations and opportunities in clinical practice. Results: 145 health areas are planned to be included, with the participation of up to 435 healthcare professionals from the 17 Autonomous Regions of Spain. Information collection will result in aggregated data from over four thousand patients. Conclusions: This observatory aims to understand how hypercholesterolemia is being treated in routine clinical practice in Spain. Even though the preliminary results show important improvement areas in the treatment of dyslipidemias, mechanisms to drive a change towards health outcomes optimization are also identified.(AU)
Asunto(s)
Dislipidemias , Protocolos Clínicos , Hipercolesterolemia/tratamiento farmacológico , Hipercolesterolemia/terapia , Evaluación de Procesos y Resultados en Atención de Salud , Hipolipemiantes , España , Práctica Clínica Basada en la EvidenciaRESUMEN
El síndrome de Diógenes constituye un reto para los clínicos. Descrito en adultos mayores, está caracterizado por el abandono extremo del autocuidado, acumulación de objetos inservibles, autonegligencia, aislamiento social y nula conciencia de la enfermedad. Entre un tercio y la mitad cursa con demencias frontotemporales o con algún trastorno mental. Se presenta el caso de un varón de 71 años que ingresa en psiquiatría por alteraciones conductuales. Presenta conducta de acumulación, abandono de higiene, desorganización y pérdida de hábitos. La conducta genera conflictos vecinales y alarma social, por lo que intervienen los servicios sociales. Las pruebas de imagen no aportan hallazgos patológicos significativos. La exploración neuropsicológica indica afectación leve de las áreas prefrontales dorsolaterales, dorsomediales y orbitofrontales. No se objetiva psicopatología aguda. Se interviene multidisciplinarmente, en formato de hospital de día, con supervisión conductual, plan de estructuración del tiempo, promoción de la autonomía y apoyo social. Este caso evidencia la complejidad del proceso diagnóstico y la movilización de recursos sociales, sanitarios y legales dadas las repercusiones en todas las áreas. (AU)
Diogenes syndrome is a challenge for clinicians. It is described in older adults. It is characterized by extreme neglect of self-care, accumulation of useless objects, self-neglect, social isolation and no awareness of illness. Between a third and a half of the patients have frontotemporal dementias or a mental disorder. We present the case of a 71-year-old male admitted to psychiatry due to behavioral disorders. He presents hoarding behavior, neglect of hygiene, disorganization and loss of habits. The behavior generates neighborhood conflicts and social alarm, for which social services intervene. Neuroimaging studies do not provide significant pathologic findings. Neuropsychological examination showed mild involvement of dorsolateral, dorsomedial, and orbitofrontal prefrontal areas. No acute psychopathology was observed. Multidisciplinary intervention is performed in a day hospital, with behavioral supervision, time structuring plan, promotion of autonomy and social support. This case shows the complexity of the diagnostic process and the mobilization of social, health and legal resources given the repercussions in all areas. (AU)
Asunto(s)
Humanos , Masculino , Anciano , Trastorno de Acumulación , Autocuidado , Aislamiento Social , Psicopatología , PacientesRESUMEN
Resumen La leishmaniasis cutánea es una enfermedad zoonótica que se transmite al hombre y a los animales a través de la picadura de insectos dípteros de los géneros Phlebotomus y Lutzomyia infectados con diferentes especies de protozoos del género Leishmania. En América Latina el principal agente etiológico responsable de esta parasitosis es la especie L. braziliensis. Si bien se han identificado numerosas especies de mamíferos infectados naturalmente con especies de Leishmania, los roedores cumplirían un rol importante en el ciclo de transmisión de la enfermedad. El presente trabajo tuvo como objetivo la identificación de especie de leishmania que circula en roedores sinantrópicos que habitan el área urbana de la ciudad de Corrientes. Se trabajó con muestras de piel de oreja de roedores a los que se les aplicó las técnicas de Nested PCR para la identificación de Leishmania spp y PCR Simple para la detección de L. braziliensis. Se analizó un total de 30 muestras de roedores de la especie Rattus rattus de los cuales 2 muestras resultaron detectables a Nested PCR. Seguidamente, a las muestras detectables a Leishmania spp. se les aplicó PCR Simple a L. braziliensis resultando ambas detectables a esta especie. Si bien los valores obtenidos en este trabajo no son altos para poder considerarlos como reservorios, si se evidencia una infección natural que no afecta clínicamente a los roedores estudiados con circulación del parásito en piel, particularmente de la especie L. braziliensis.
Abstract Cutaneous leishmaniasis is a zoonotic disease that is transmitted to man and animals through the bite of dipteran insects of the genera Phlebotomus and Lutzomyia infected with different species of protozoa of the genus Leishmania. In Latin America the main etiological agent responsible for this parasitosis is the species L. braziliensis. Although numerous species of mammals have been identified naturally infected with Leishmania species, rodents would play an important role in the transmission cycle of the disease. The present work aimed to identify the species of leishmania that circulates in synanthropic rodents that inhabit the urban area of the city of Corrientes. We worked with rodent ear skin samples to which the Nested PCR techniques were applied for the identification of Leishmania spp and Simple PCR for the detection of L. braziliensis. A total of 30 rodent samples of the species Rattus rattus were analyzed, of which 2 samples were detectable by Nested PCR. Next, the samples detectable to Leishmania spp. Simple PCR was applied to L. braziliensis, both of which were detectable in this species. Although the values obtained in this work are not high to be considered as reservoirs, there is evidence of a natural infection that does not clinically affect the rodents studied with circulation of the parasite on the skin, particularly of the L. braziliensis species.
RESUMEN
INTRODUCCIÓN: La marcha de puntillas idiopática (MPI) se describe como el patrón de marcha sin apoyo del talón en niños mayores de 3 años. El diagnóstico es clínico y obliga a descartar otras enfermedades neurológicas y traumatológicas-ortopédicas. Se postula su relación con una disfunción vestibular o de sensibilidad propioceptiva. Los niños con trastornos del neurodesarrollo (trastorno del espectro autista, trastorno del lenguaje y cognitivo) presentan frecuentemente MPI. OBJETIVOS: Analizar la frecuencia de MPI en niños con trastorno por déficit de atención e hiperactividad (TDAH). Pacientes y método: Estudio en niños diagnosticados de TDAH con exploración neurológica normal, sin alteraciones en neuroimagen ni trastorno cognitivo o trastorno del espectro autista. Se realizó anamnesis completa y se valoró la presencia de acortamiento aquíleo con goniómetro. RESULTADOS: Se analizó a 312 niños con edad media de 11 años, el 73,7% varones. El subtipo combinado fue el más frecuente (53,8%), seguido del inatento (44,9%) e hiperactivo (1,3%). Un 20,8% de los pacientes presentaban MPI, que era más frecuente en el subtipo combinado (p = 0,054). Solo 32 de estos (49,2%) presentaban acortamiento aquíleo. La presencia de MPI se relacionó con alteraciones en el área de la sociabilidad (p = 0,01), ausencia de dolor en miembros inferiores (p = 0,022) y antecedentes familiares de MPI (p = 0,004). Solo el 11% habían consultado por este motivo previamente. CONCLUSIONES: Al igual que en otros trastornos del neurodesarrollo, los niños con TDAH presentan con mayor frecuencia MPI y acortamiento aquíleo, especialmente entre aquellos con trastornos de comunicación social o antecedentes familiares de MPI. Es fundamental una identificación precoz para instaurar tratamientos eficaces
INTRODUCTION: Idiopathic toe-walking (ITW) is described as a gait pattern with no contact between the heels and the ground in children older than 3 years. The diagnosis is clinical, making it necessary to rule out other neurological and orthopaedic conditions. A relationship between ITW and vestibular dysfunction and/or proprioceptive sensibility has been proposed. Children with neurodevelopmental disorders (autism, language and cognitive disorders) often have ITW. OBJECTIVES: To determine the frequency of ITW in children with attention deficit disorder and hyperactivity (ADHD). PATIENTS AND METHOD: A study was conducted on children diagnosed with ADHD, with normal neurological examination, with no alterations in MRI scan, cognitive disorder or autism. A complete clinical anamnesis was performed and Achilles shortening was measured with a goniometer. RESULTS: The study included 312 children with a mean age of 11 years (73.7% boys). The ADHD combined subtype was the most frequent (53.8%), followed by the inattentive (44.9%), and hyperactive (1.3%). ITW was observed in 20.8% of patients, particularly in the combined subtype (P=.054). Only 32 of them (49.2%) had Achilles shortening. ITW was associated with sociability disorders (P=.01), absence of pain in legs (P=.022), and family history of ITW (P=.004). Only 11% had previously visited a doctor for this reason. CONCLUSIONS: As in other neurodevelopmental disorders, children with ADHD have frequently more ITW and Achilles shortening than controls, especially if they presented with a social communication disorder or a family history of ITW. An early diagnosis is essential to establish effective treatments
Asunto(s)
Humanos , Masculino , Femenino , Niño , Adolescente , Marcha , Trastorno por Déficit de Atención con Hiperactividad/fisiopatología , Desempeño Psicomotor/fisiología , Psicometría/métodos , Anamnesis/métodos , Biometría/métodosRESUMEN
No disponible